Aim To examine the risk to heroin users of also using gabapentin or pregabalin (gabapentoids). Design Multidisciplinary study: we (a) examined trends in drug-related deaths and gabapentoid prescription data in England and Wales to test for evidence that any increase in deaths mentioning gabapentin or pregabalin is associated with trends in gabapentoid prescribing and is concomitant with opioid use; (b) interviewed people with a history of heroin use about their polydrug use involving gabapentin and pregabalin; and (c) studied the respiratory depressant effects of pregabalin in the absence and presence of morphine in mice to determine whether concomitant exposure increased the degree of respiratory 79% of these deaths also involved opioids. The increase in deaths was correlated highly with the increase in prescribing (correlation coefficient 0.94; 5% increase in deaths per 100 000 increase in prescriptions). Heroin users described pregabalin as easy to obtain. They suggested that the combination of heroin and pregabalin reinforced the effects of heroin but were concerned it induced 'blackouts' and increased the risk of overdose. In mice, a low dose of S-pregabalin (20 mg/kg) that did not itself depress respiration reversed tolerance to morphine depression of respiration (resulting in 35% depression of respiration, P < 0.05), whereas a high dose of S-pregabalin (200 mg/kg) alone depressed respiration and this effect summated with that of morphine. Conclusions For heroin users, the combination of opioids with gabapentin or pregabalin potentially increases the risk of acute overdose death through either reversal of tolerance or an additive effect of the drugs to depress respiration.
INTRODUCTION
The gabapentoids, gabapentin and pregabalin, are first-line treatments for various forms of neuropathic pain and are licensed for the treatment of some forms of epilepsy. They are also used widely off-label for other disorders including anxiety (pregabalin), insomnia, migraine, mania, bipolar disorder and alcohol withdrawal (gabapentin). These drugs were classified originally as having low abuse potential.
However, there have been reports of gabapentin and pregabalin being misused, with subsequent development of dependence [1] [2] [3] [4] and recent reports of gabapentin and pregabalin misuse in subjects with a history of opioid use [5] [6] [7] [8] [9] . Behavioural effects of these drugs related to their misuse include relaxation, enhanced sociability, euphoria and, at higher doses, dissociation and sedation.
Concerns about over-prescribing of gabapentin and pregabalin led Public Health England and NHS England to issue prescribing advice for these drugs in 2014 [10] . Clinical guidelines on the management of neuropathic pain in both general and special settings (such as prisons) have emphasized caution in the use of gabapentoids because of their potential for misuse and diversion; however, the specific issue of increased overdose death has not been emphasized in this context [11, 12] . A study of toxicology reports of drug-related deaths in Finland in 2010-2011 [13] suggested there had been a substantial increase in drug-related deaths involving pregabalin and opioids. In two opioid treatment programmes in Ireland and Germany, 10% of patients tested positive for pregabalin by urine analysis, the majority without being prescribed the drug for any medical purpose [5, 6] .
We conducted a multi-disciplinary study to examine the risk of polydrug use involving opioids and pregabalin or gabapentin. We examined trends in the number of drug-poisoning deaths in England and Wales to assess whether there has been an increase in the number of pregabalin or gabapentin fatal poisonings and whether the increase is associated with concomitant opioid use. People with a history of heroin use were interviewed about their use of pregabalin and gabapentin, and their perception of the dangers of co-use with opioids. We also determined in mice the respiratory depressant effects of pregabalin in the absence and presence of morphine to determine if concomitant use increased the likelihood of overdose death from respiratory depression.
METHODS

Drug-related poisoning deaths
The Office for National Statistics (ONS) has developed a database of drug-related deaths in England and Wales (based on International Classification of Disease codes) that identifies the specific substances involved [14, 15] . The information is obtained from death certificates issued by coroners after investigation of the death, supported by forensic toxicology. ONS has access only to information specified on the death certificate, and does not have access to the full toxicology report. Guidance on the limitations of the data held by ONS are given in ONS 2016 [15] . Data concerning the number of drug-related deaths where pregabalin or gabapentin were mentioned, and whether or not the record also mentioned an opioid, were extracted for deaths registered between 1 January 2004 and 31 December 2015. The number of community prescriptions per annum for pregabalin and gabapentin in England and Wales were obtained from the Health and Social Care Information Centre (HSCIC). We used correlation coefficient and linear regression to test whether there was a positive association between trends in gabapentoid prescription and drug-related deaths mentioning pregabalin or gabapentin. Drug-related deaths data had 1 added to each year record (because no deaths were observed in 2005, 2007 and 2008) and were then logtransformed, so that residuals from the linear regression model were distributed normally [16] . As a sensitivity analysis around the addition of 1 as a constant to the death data, we re-ran the regression model after dropping the year records with no deaths.
Interviews with heroin users
The Bristol Drugs Project (BDP), the selected location for this study into polydrug abuse among heroin users, is located close to Bristol city centre and offers a range of facilities for service users who are on varying drug treatments and at different stages of treatment. The study was approved by the Faculty of Medical and Dentistry Committee for Research Ethics, University of Bristol.
A purposive sample (based on gender and duration of heroin use) were given information about the study and asked if they would be willing to take part in an interview. The staff of BDP had good background knowledge of how long people had been using heroin and assisted in identifying eligible participants. No one who was approached actively rejected participating in the study, although three individuals who had agreed verbally to take part did not attend for interview at their allocated time. No one withdrew from the study once written consent was given.
Interviews were conducted with 30 participants. The sample size was partly pragmatic in terms of the study time-table, but was designed to include a range of heroin users. Data saturation was reached, in that no new issues were emerging towards the end of the interview process. The final sample comprised 19 males and 11 females, of whom 20 were long-term drug users who had used heroin for more than 10 years; four had used heroin between 5 and 10 years; and six were shorter-term drug users who had used heroin for less than 5 years. Each participant was interviewed once by A.L. between October 2014 and February 2015, and was given £10 to compensate them for their time. Interviews were conducted in a private consultation room and recorded digitally with the written consent of the participant. Interviews lasted between 8 and 52 minutes, with the mean length of interview being 25 minutes (excluding the initial introduction and consent procedures). All interviews were conducted by the same researcher (A.L.) using a topic guide designed to identify patterns and types of polydrug use, and participants' perceptions of any benefits and disadvantages to polydrug use.
Recordings were transcribed verbatim, anonymized and transferred into Nvivo10 software (QSR International, Southport, UK) to aid analysis. Thematic analysis was undertaken using Framework and Nvivo software [17] . Sections of text were coded by A.L. according to specific drugs used and participants' perceptions of their interactions and effects. S.A. checked coding and interpretation, with any discrepancies resolved through discussion between A.L. and S.A. Data presented here relate to the key themes identified in relation to polydrug use involving gabapentoids.
Respiration studies
Male CD-1 mice (Harlan Laboratories, Shardlow, UK) weighing approximately 30 g were maintained at 22°C on a reversed 12-hour dark : light cycle with food and water available ad libitum. All experiments were performed in the dark (active) phase. Animals were ascribed randomly to treatment groups (n = 6 or 7), with the experimenter blinded to the drug treatment. Respiration was measured in freely moving animals using plethysmography chambers (EMKA Technologies, Paris, France) supplied with a 5% CO 2 in air mixture (BOC Gas Supplies, Leeds, UK), as described previously [18] . Rate and depth of respiration were recorded and converted to minute volume (MV). Only animals whose initial pre-drug MV was between 120 and 185 ml/min were included in this study. Data were analysed using an unpaired Student's t-test and a statistically significant difference assumed when P < 0.05. All procedures were performed in accordance with the UK Animals (Scientific Procedures) Act 1986, the European Communities Council Directive 1986 (86/609/EEC) and the University of Bristol ethical review document.
Drugs used were morphine hydrochloride (Macfarlan Smith, Edinburgh, UK), naloxone hydrochloride (Sigma Aldrich, Poole, UK) and S/R-pregabalin and S-pregabalin (synthesized and purified at the University of Bristol). S/R-pregabalin was used in our initial experiments, but we switched to S-pregabalin (the active isomer) when sufficient stocks became available. To induce tolerance to morphine mice were either implanted subcutaneously with a morphine pellet (75 mg morphine base; National Institute on Drug Abuse, Bethesda, MD, USA) or an osmotic minipump (Alzet, Cupertino, CA, USA) that released morphine 45 mg/kg/day for 6 days [18] . Figure 1a shows trends in the number of prescriptions for gabapentoids (pregabalin and gabapentin) in 100 000s, with the number of drug-related deaths mentioning gabapentoids in total and those mentioning gabapentoids and opioids. There has been an annual 24% increase in the number of gabapentoid prescriptions in England and Wales from approximately 1 million in 2004 to 10.4 million in 2015. Deaths in which pregabalin or gabapentin was mentioned on the death certificate increased from fewer than one per year before 2009 to 137 deaths in 2015. In 79% of these deaths (216 of 275), opioids (heroin, methadone, other or non-specified) were also mentioned. The increase in deaths was correlated highly with prescribing data (correlation coefficient 0.94; Fig. 1b ). For each 100 000 increase in gabapentoid prescription, the number of deaths increased by approximately 5% [risk ratio (RR) = 1.05, 95% confidence interval (CI) = 1.03-1.06, P < 0.001], which is equivalent to a RR of 1.64 for an increase of 1 million prescriptions and an RR of 88.4 for an increase of 8 million prescriptions. After transforming the deaths data there was no evidence of non-normality (Shapiro-Wilk W test for normal data, P = 0.75; Cameron & Trivedi's test against heteroskedasticity, P = 0.11. Excluding years without any deaths did not alter the findings (correlation coefficient = 0.965; RR = 1.047).
RESULTS
Deaths involving pregabalin and gabapentin
Heroin users' perceptions of combining heroin and pregabalin or gabapentin
All interview participants were, or had been, active heroin users and some were on an opioid substitution treatment. Participants reported ease of access to gabapentoids. Of the 30 participants interviewed, 21 had experience of pregabalin or gabapentin. Two participants used gabapentin, stating that they used it daily and sourced it from friends who were prescribed it. Of the 19 pregabalin users, one was a daily user; three used it weekly; five used it rarely; and 10 stated it was just a one-off occasion. Pregabalin was taken orally in tablet form, and doses ranged from 300 to 1500 mg. Some participants said they were prescribed pregabalin by a doctor, usually as they had some kind of nerve damage from previous accidents, but others suggested that pregabalin could be purchased on the street for approximately £2 per 300 mg tablet.
Pregabalin enhances the effect of heroin
Participants highlighted growing recognition that the combination of heroin and pregabalin could enhance the effect of the heroin. Ian, aged 51, a long-term heroin user who took pregabalin on a daily basis, indicated: 'I'm prescribed it for a reason, for nerve damage but I didn't know what was going on until later on, later on like in my using, that it was enhancing, enhancing the feeling of the heroin whereas I thought it was just better heroin [laughs] at the time. So I was naive to the fact of that but now I'm well, well, well versed in like knowing what that is all about'. Similarly, Edward, aged 34 and a short-term heroin user who took pregabalin rarely, suggested: 'If anything the heroin's helped the pregabalin work quicker and maybe stronger… so they both sort of work same sort of way'.
Pregabalin might reduce heroin use
Because of the belief that the drugs had similar effects, it was asserted that pregabalin might decrease heroin use for some people. James, aged 58 and a long-term heroin user, said he had used pregabalin three times and added:
'You don't really want to use heroin, you want more pregabs, I don't know why'. Kate, aged 35, a long-term heroin user who said she had rarely taken pregabalin, suggested it might assist with heroin withdrawal: 'Last time I used I took two, two of 250 pregabalins and I went home. And I've got two of each [heroin and crack cocaine] in my pocket for instance, yeah. Put it down on the coffee table and normally I would be desperateopen it up, you know, doing it. I just, I was just so like chilled out watching TV and the next thing I know I woke up the next morning and the two things, four things [heroin and crack cocaine] were still on the table and I felt really good about myself, I hadn't used because, for some reason. And loads of other addicts have said the same to me as well. It [pregabalin] would be a brilliant drug to bring out in a detox unit, just to be used for like one or two days, just when you're feeling the shittiest, because it really, it really does, it just chills you out'.
Pregabalin causes blackouts/loss of control
The combination of heroin and pregabalin was thought to be the cause of blackouts and loss of control. Cleo, aged 23 and a short-term heroin user, said she had rarely used pregabalin: 'The effect on me it's like I had blackouts because the next day I wakes up and I can't remember nothing what happened'. Edward, aged 34 and a shortterm heroin user, also said he rarely used pregabalin: 'Most people that I know who's took pregabalin around me, cos I've not took many myself but I've known people who takes them to get wrecked, is um they're like zombies, they don't know what they're doing'.
Concerns were raised that these blackouts could have serious implications for the user. Jacob, aged 44 and a long-term heroin user who used pregabalin on a weekly basis, suggested: 'By the time it hits the pregabs you're already out of your head so, you know what I mean, you could end up doing a hit that you wouldn't usually do because you're not really with it'.
Pregabalin and overdose
Of the participants who took pregabalin, most believed it increased the risk of overdose. Ian, aged 51 and a longterm heroin user, used pregabalin daily: 'That's one of my last overdoses. I knew the heroin was strong and I didn't know, I was naive to the fact, that pregabalin is an enhan-is an enhancer as well as what it's used for medically like on my body'. Helen, aged 36 and another long-term heroin user who took pregabalin every day, suggested that pregabalin had a delayed effect which could increase the risk of overdose for an impatient user: 'Pregabalin takes like two, three hours to kick in so, like, and then we think "Argh it hasn't kicked in, I'll have a dig". So we have a dig and then that kicks in and then there's more chance of you going over... overdosing, that's the danger'.
Effect of pregabalin on respiration
Pregabalin depression of respiration
The heroin users we interviewed indicated a preference for pregabalin, and therefore we examined the effects of pregabalin rather than gabapentin on respiration in mice. In the early stages of the study we only had S/Rpregabalin available to us. We observed that S/Rpregabalin [40-400 mg/kg intraperitoneally (i.p.)] produced dose-dependent depression of respiration. When S-pregabalin, the active pregabalin isomer in Lyrica [19] , became available we demonstrated that a 200 mg/kg dose of this isomer produced similar respiratory depression to 400 mg/kg of the racemate (compare the depression of respiration by pregabalin in Figs 2b and  3b) . S-pregabalin produced profound depression of respiration that developed rapidly, within 5 minutes of drug injection, and was maintained for the remainder (30 minutes) of the observation period (Fig. 2a,b) . When respiration was depressed by pregabalin it became regular, there was no evidence of apnoea or gasping, and resulted from a decrease in both rate and depth of respiration (Fig. 2c) . Pregabalin did not induce ribcage muscle stiffness, which would reduce tidal volume. The depression of respiration by 200 mg/kg S-pregabalin was similar to that induced by 10 mg/kg morphine (Fig. 2b) . The depression of respiration by pregabalin was not due, however, to release in the brain of endogenous opioids or to direct activation of opioid receptors as, unlike the depression which occurs to morphine, it was not prevented by prior administration of naloxone (Fig. 3a) .
When administered to the same animal the respiratory depressant effects of S/R-pregabalin and morphine appeared to summate rather than show synergism (Fig. 3b) . The depression of respiration by morphine after S/R-pregabalin was similar in extent to that seen in animals not pre-treated with S/R-pregabalin (Fig. 3c) . In mice that had been rendered tolerant to morphine by continuous exposure to the drug over 6 days, S/R-pregabalin produced the same degree of respiratory depression as seen in morphine-naive mice (Fig. 3d) .
Pregabalin reversal of morphine tolerance
Following 6 days' treatment with morphine an acute challenge with morphine (10 mg/kg) failed to depress respiration, demonstrating that the mice were tolerant (compare Figs 2b and 4b) . To investigate the effect of pregabalin on morphine tolerance, we gave mice that had been treated with morphine for 6 days an acute injection of S-pregabalin (20 mg/kg i.p.) at the same time as the challenge dose of morphine. This dose of S-pregabalin alone produced very little depression of respiration in both naive mice and mice pre-treated with morphine (Fig. 4a) . In morphine-pre-treated mice that were injected with S-pregabalin at the same time as the acute morphine challenge, respiration was depressed significantly (Fig. 4b) . This is consistent with pregabalin reversal of morphine tolerance.
DISCUSSION
Main findings
Concomitant use of heroin and gabapentoids (pregabalin and gabapentin) is an emerging public health problem. Fatal poisonings, the majority involving opioids, have increased substantially and are correlated strongly with the increase in prescriptions. Heroin users reported ease of access and increasing use of gabapentoids which, if taken with heroin, can induce blackouts and may increase overdose risk. In laboratory animal experiments, a low dose of pregabalin was observed to reverse morphine tolerance and reveal respiratory depression to a dose of morphine that did not depress respiration in tolerant animals, whereas a high dose of pregabalin itself depressed respiration in opioid-naive animals and this was additive with morphine. Taken together, our data corroborate the hypothesis of an increase in overdose risk when gabapentoids are used along with opioids.
Strengths and limitations
We are unaware of any other studies that combine epidemiological, qualitative and pharmacological laboratory experimental insights on overdose risk, and believe our study demonstrates the benefits of combining different research methods in the study of risk. However, there are limitations that need to be taken into account. Information on drug-related poisonings is based on drugs specified by the coroner on the death certificate. Approximately 10% of poisoning deaths have no specific information, and not every drug detected in forensic tests will be reported on the death certificate [20] . Approximately one in three fatal poisonings mention more than one substance and 30% mention alcohol, and it is not always clear which substance or substances is responsible for the fatality [15] . We are not aware, however, of any alteration in practice by coroners that would increase the likelihood of reporting pregabalin or gabapentin on death certificates. We show a strong ecological association between trends in gabapentoid prescriptions and overdose deaths, but from the data available to ONS we are unable to say how many acute poisoning deaths in which both opioids and gabapentoids were reported are illicit opioid users or how many are patients prescribed both opioids and gabapentoids for pain. The majority of people dying from opioid poisoning, however, are problem drug users. Moreover, given the ready availability of gabapentoids to illicit opioid users (as reported in our interviews with heroin users) and the perceived higher incidence of overdose (non-fatal and fatal) among illicit opioid users it is likely that they are the larger cohort.
Our interviews with heroin users were, by necessity, undertaken on a relatively small sample of participants and cannot be generalized to a wider population. However, we were able to interview a range of heroin users of both genders whose accounts are authentic and provide insight into the views and experiences of polydrug use involving heroin and gabapentoids. Finally, in the study of the effect of pregabalin on respiration, we did not attempt to determine the mechanism by which the observed depression occurred save that it was produced by S-pregabalin, the active isomer of pregabalin used clinically in the treatment of pain, and that it did not involve either the release of endogenous opioids or direct activation of opioid receptors.
How our evidence fits with other studies
An association between the presence at post mortem of opioids and gabapentoids has been observed previously in a Finnish study of drug-related deaths [13] . They observed that opioids were present in approximately 90% of the deaths where there was evidence of pregabalin or gabapentin misuse. They also reported that the incidence of pregabalin misuse in drug-related deaths was more than sevenfold greater than that of gabapentin. This may be because pregabalin is absorbed more rapidly and has higher bioavailability than gabapentin following oral administration [21] .
Potentially, the presence of pregabalin or gabapentin in opioid overdose fatalities could have been benign and not a factor in overdose, their presence simply being due to recent misuse of these drugs by heroin users. However, there is now evidence from multiple sources that gabapentoids potentiate the effects of opioids. A survey of opioid users suggested that pregabalin and gabapentin potentiated the high obtained with methadone [22] . Also, the heroin users we interviewed reported that gabapentoids enhanced both the high and the likelihood of overdose.
In animal experiments, pregabalin has been reported to enhance the sedation induced by oxycodone and morphine [23] , while gabapentin can inhibit both the development and maintenance of tolerance to the antinociceptive effects Figure 3 Interactions between S/R-pregabalin and morphine on mouse respiration. (a) Pre-treatment with naloxone (nal) [1 mg/kg intraperitoneally (i.p.), nal] for 10 min abolished the depression of respiration induced by morphine (mor) (10 mg/kg i.p., mor) but not that induced by S/R-pregabalin (400 mg/kg i.p., pregab). The area under the curve (AUC) for the percentage change in minute volume induced by each drug treatment was calculated (see [18] ) and then the mean value determined; n = 6 in each case. *Indicates P < 0.05, unpaired, two-tailed Student's t-test comparing morphine and morphine + naloxone. There was no statistical difference between pregabalin and pregabalin + naloxone. (b) Depression of respiration induced by morphine (10 mg/kg i.p., filled squares) or saline (filled circles) in mice that had been pre-treated with S/R-pregabalin (400 mg/kg i.p.). (c) Comparison of the depression of respiration induced by morphine in naive animals and in animals pre-treated with S/R pregabalin (400 mg/kg); n = 6 in each case. There was no statistical difference (unpaired, two-tailed Student's t-test) between the treatments. (d) Depression of respiration induced by S/Rpregabalin (400 mg/kg i.p.) in naive mice and in mice that had been pre-treated with morphine for 6 days; n = 7 in each case. Statistical analysis (unpaired, two-tailed Student's t-test) of the AUC for both treatments demonstrated that there was no statistical difference between the degree of respiratory depression induced by pregabalin in the naive and morphine-treated mice.
of morphine [24] . We observed that morphine and pregabalin were additive in depressing respiration, and a low dose of pregabalin could reverse tolerance to the respiratory depressant effects of morphine. Both these effects would result in enhanced respiratory depression and supports further the view that gabapentoids can contribute to heroin fatalities.
Implications
Heroin users are notorious polydrug users frequently using alcohol, benzodiazepines and crack cocaine as well as heroin [25] . To this list we can now add the gabapentoids, which are prescribed widely for a range of disorders. The substantial rise in prescriptions illustrated in Fig. 1 seems unlikely to be due simply to an increase in cases of neuropathic pain [26] . Their uncontrolled status may lead to over-prescribing, particularly to those with a history of substance/opioid misuse [4] . Also, the absence of objective parameters for the severity of the conditions for which pregabalin and gabapentin are prescribed may make it easy to obtain high doses of these drugs, simply by reporting poor effectiveness or by reporting symptoms that do not exist [8] . This may also facilitate diversion. Although guidelines for pain management recommend caution in the use of gabapentoids because of the risk of misuse and diversion, these issues are not highlighted in current guidance on the management of opioid dependence. Similarly, the specific problem of increased overdose risk associated with gabapentoids is not emphasized in current overdose prevention guidelines for problem opioid users. In contrast, the increase in methadone prescription after the introduction of supervised consumption was not associated with an increase in methadone-related overdose deaths [27] . In the broader context, these issues reflect the challenge of the management of chronic noncancer pain in the community. Pain is a symptom and is not amenable to objective measurement. Chronic pain, including 'neuropathic' pain, is extremely common and is managed mainly by clinical generalists working in primary care [28] . Faced with an apparently distressed and demanding patient who reports that their pain has not been controlled by other treatments, general In mice that had been pre-treated with morphine for 6 days, acute injection of morphine (10 mg/kg i.p.) did not depress respiration, i.e. the mice were tolerant whereas, with a simultaneous injection of pregabalin (20 mg/kg i.p.) injection of morphine (10 mg/kg i.p.) did depress respiration in mice that had been pre-treated with morphine for 6 days. (c) The area under the curve (AUC) analysis of the data in (a) and (b) (see [18] ) indicated that in morphine-pre-treated mice pregabalin + morphine induced significantly greater depression of respiration than morphine alone (P < 0.05); n = 6 in each case.
practitioners may feel pressure to prescribe an alternative, particularly when there is some evidence that this alternative is effective [29] .
Gabapentin or pregabalin are currently being prescribed to heroin users, or can be purchased on the street. It is important that doctors and their patients are aware that the combination of opioids with gabapentin or pregabalin potentially increases the risk of acute overdose death through either reversing tolerance or by an additive effect of the drugs to depress respiration. Alternatives to gabapentoids need to be recommended for clinicians managing opioid-dependent patients with neuropathic pain or generalized anxiety, and greater attention given to restricting diversion of gabepentoid prescriptions.
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